BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Cerimon Pharmaceuticals, Inc. 

701 Gateway Boulevard
Suite 100
South San Francisco  California  94080  U.S.A.
Phone: 650-827-4000 Fax: 650-827-4040


SEARCH JOBS

View Clinical Trials from BioPharm Insight




Segment
Start Up





 Company News
Cerimon Pharmaceuticals, Inc. Acquires European Rights to its Topical Diclofenac Sodium Patch 11/10/2009 6:15:39 AM
Cerimon Pharmaceuticals, Inc. Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain 2/25/2009 9:07:47 AM
Cerimon Pharmaceuticals, Inc. Appoints James S. Shannon, M.D., to Board of Directors 12/2/2008 10:16:27 AM
Cerimon Pharmaceuticals, Inc. Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain 9/11/2008 6:35:32 AM
Cerimon Pharmaceuticals, Inc. Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis 7/9/2008 7:58:16 AM
Cerimon Pharmaceuticals, Inc. to Conduct a Proof of Concept Study for Basiliximab for Noninfectious Uveitis, a Potentially Sight-Threatening Inflammation of the Eye 3/10/2008 8:01:01 AM
Cerimon Pharmaceuticals, Inc. Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain 1/16/2008 7:18:12 AM
Cerimon Pharmaceuticals, Inc. Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing 1/4/2008 8:24:34 AM
Cerimon Pharmaceuticals, Inc. to Present at the 2007 Biotechnology Industry Organization (BIO) Investor Forum 10/5/2007 10:11:19 AM
Cerimon Pharmaceuticals, Inc. Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch 10/2/2007 8:11:16 AM
123